Pure Global
NCT06263946

Essilor® Stellest® Lenses Multicentre European Study (SLOMES)

Post Market Clinical Follow-up Study to Demonstrate the Efficacy, Safety, Acceptability and Quality of Life Implications of Essilor® Stellest® Spectacle Lenses in Slowing Myopia Progression in Children and Adolescents.
Essilor International·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Myopia
Drug/Device/Intervention
Essilor® Stellest® spectacle lenses
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Essilor International
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2024
End date
Dec 30, 2026
Enrollment
150 participants
Primary outcome

Change in cycloplegic axial length,Change in cycloplegic autorefraction

Summary

The goal of this post-market clinical follow up Study is to demonstrate the efficacy, safety,
 acceptability, and quality of life implications of Essilor® Stellest® spectacle lenses in
 slowing myopia progression in European children and adolescents. Participants will receive
 Essilor® Stellest® at inclusion visit and will be asked for a full time wear (12 hours
 daily) for 24 months. The primary endpoints are the change in axial length and cycloplegic
 autorefraction from baseline to 24 months compared to expected change based on axial length
 and refraction centile positions at baseline.

ICD-10 classifications
MyopiaDegenerative myopiaAmblyopia ex anopsiaOcular myiasisMyiasis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06263946
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06263946 through Pure Global AI's free database. This phase not specified trial is sponsored by Essilor International and is currently Not yet recruiting. The study focuses on Myopia. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.